Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.

Outcomes in older patients with acute myeloid leukemia (AML) have historically been poor. Given advances in low-intensity therapy (LIT) and stem cell transplantation (SCT), we performed a retrospective single-center study to evaluate the contemporary outcomes of this population. We reviewed all patients ≥60 years with newly diagnosed AML between 2012 and 2021 and analyzed treatment and SCT-related trends and outcomes. We identified 1073 patients with a median age of 71 years. Adverse clinical and cytomolecular findings were frequent within this cohort. In total, 16% of patients were treated with intensive chemotherapy, 51% with LIT alone, and 32% with LIT plus venetoclax. The composite complete remission rate with LIT plus venetoclax was 72%, which was higher than with LIT alone (48%, p < .0001) and comparable to intensive chemotherapy (74%, p = .6). The median overall survival (OS) with intensive chemotherapy, LIT, and LIT plus venetoclax was 20.1, 8.9, and 12.1 months, respectively. 18% of patients received SCT. SCT rates were 37%, 10%, and 22% in patients treated with intensive chemotherapy, LIT, and LIT plus venetoclax, respectively. The 2-year OS, relapse-free survival (RFS), cumulative incidence (CI) of relapse, and CI of treatment-related mortality with frontline SCT (n = 139) were 59%, 52%, 27%, and 22%, respectively. By landmark analysis, patients undergoing frontline SCT had superior OS (median 39.6 vs. 21.4 months, p < .0001) and RFS (30.9 vs. 12.1 months, p < .0001) compared with responding patients who did not. Outcomes in older patients with AML are improving with more effective LIT. Measures should be pursued to increase access to SCT in older patients.

[1]  D. Neuberg,et al.  A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia , 2022, Blood.

[2]  K. Bhalla,et al.  Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study , 2022, Blood.

[3]  N. Heerema,et al.  A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML) , 2022, Blood.

[4]  E. Estey,et al.  An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients. , 2022, Blood.

[5]  B. Ebert,et al.  Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. , 2022, Blood.

[6]  P. Vyas,et al.  AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. , 2022, Clinical lymphoma, myeloma & leukemia.

[7]  M. Konopleva,et al.  Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML , 2022, Blood Cancer Journal.

[8]  C. Hourigan,et al.  Age is no Barrier for Adults undergoing HCT for AML in CR1: Contemporary CIBMTR Analysis , 2022, Bone Marrow Transplantation.

[9]  M. Konopleva,et al.  Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy , 2022, Blood cancer journal.

[10]  M. Konopleva,et al.  Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML , 2021, Blood.

[11]  M. Konopleva,et al.  Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy. , 2021, American journal of hematology.

[12]  C. McMahon,et al.  Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia , 2021, Blood advances.

[13]  P. Chevallier,et al.  In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study , 2021, Blood advances.

[14]  K. Rezvani,et al.  Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. , 2021, Transplantation and cellular therapy.

[15]  M. Konopleva,et al.  Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia , 2021, American journal of hematology.

[16]  M. Konopleva,et al.  Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality , 2020, American journal of hematology.

[17]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[18]  G. Guyatt,et al.  American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. , 2020, Blood advances.

[19]  J. Novak,et al.  Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. , 2020, Blood.

[20]  N. Vey.  Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia , 2020, Therapeutic advances in hematology.

[21]  Qi Zhang,et al.  Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. , 2020, Blood.

[22]  I. Weissman,et al.  Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency , 2019, Blood.

[23]  Stephanie J. Lee,et al.  Transplant Center Characteristics And Survival After Allogeneic Hematopoietic Cell Transplantation In Adults , 2019, Bone Marrow Transplantation.

[24]  I. Weissman,et al.  Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. , 2019, Blood.

[25]  I. Weissman,et al.  Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. , 2019, Blood.

[26]  Susan O'Brien,et al.  Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. , 2018, The Lancet. Haematology.

[27]  B. Gyawali,et al.  Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia , 2018, Bone Marrow Transplantation.

[28]  E. Estey,et al.  Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality , 2017, JAMA oncology.

[29]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[30]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[31]  C. Reyes,et al.  Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States , 2015, Annals of Hematology.

[32]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Williamson,et al.  Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. , 2010, Blood.

[34]  M. Labopin,et al.  Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[36]  E. Estey,et al.  Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). , 2007, Blood.

[37]  H. Kantarjian,et al.  The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. , 2007, British journal of haematology.

[38]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.

[39]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  H. Deeg,et al.  Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[42]  E. Thomas.  Bone marrow transplantation. , 1987, CA: a cancer journal for clinicians.